[AI Drug Discovery Startup Isomorphic Labs in Funding Talks, Valued at At Least $40 Billion] According to Deep Tide TechFlow, on October 8, Alphabet's AI drug discovery company Isomorphic Labs, led by Demis Hassabis, is in early discussions for a new round of funding, with a valuation of at least $40 billion, potentially reaching $50 billion. The company previously completed a $2.1 billion Series B funding round in May of this year. The report also noted that the application of AI in the biopharmaceutical field is still in its early stages, requiring more effort before reaching clinical trials and product launches. The current talks are in the preliminary phase, and specific terms and information about investors have not been disclosed.